DAX25.262 +0,5%Est505.997 +1,6%MSCI World4.343 -0,1%Top 10 Crypto12,29 +0,8%Nas23.682 +0,9%Bitcoin77.694 -0,4%Euro1,1637 -0,2%Öl63,10 +0,6%Gold4.506 +0,6%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 NVIDIA 918422 Novo Nordisk A3EU6F Bayer BAY001 Deutsche Telekom 555750 DroneShield A2DMAA Allianz 840400 Amazon 906866 RENK RENK73 Siemens Energy ENER6Y BASF BASF11 Lufthansa 823212 Volkswagen (VW) vz. 766403 TUI TUAG50 Infineon 623100
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
US-Börsen mit Aufwärtsdrang -- DAX schließt nach Rekord höher -- Tilray übertrifft Erwartungen -- TUI, Alphabet, BMW, BioNTech, Rheinmetall, DroneShield, Glencore, Rio Tinto, Merck & Co. im Fokus
Top News
Einfach in Krypto investieren - mit dem Top 10 Crypto ETP von finanzen.net und CoinShares Einfach in Krypto investieren - mit dem Top 10 Crypto ETP von finanzen.net und CoinShares
Konsolidierung statt Rekordjagd? Die Silber-Prognose der Commerzbank für 2026 Konsolidierung statt Rekordjagd? Die Silber-Prognose der Commerzbank für 2026
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Neurocrine Biosciences Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
116,35 EUR +0,15 EUR +0,13 %
STU
135,87 USD +0,33 USD +0,24 %
BTT
Neurocrine Biosciences jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.12,03 Mrd. EUR

KGV41,47Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN900964

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS64125C1099

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolNBIX

Neurocrine Biosciences Aktien News

DatumMeistgelesen
PR NewswireNeurocrine Biosciences Announces Publication of Primary CAHtalyst™ Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
PR NewswireNeurocrine Biosciences to Participate at Investor Conferences in June
PR NewswireNeurocrine Biosciences Announces CEO Succession Plan
PR NewswireNeurocrine Biosciences to Present New Phase 3 CAHtalyst™ Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH a...
PR NewswireNeurocrine Biosciences Announces Publication of Phase 3 KINECT®-4 Post Hoc Analysis Demonstrating Clinically Meaningful and Sustained Improvement in Tardive Dyskinesia With Long-Term Use of INGREZ...
PR NewswireNeurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024
PR NewswireNeurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024
PR NewswireNeurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults
PR NewswireNeurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults
PR NewswireNeurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference
PR NewswireNeurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insuffic...
PR NewswireNeurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring
PR NewswireNeurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024
PR NewswireNeurocrine Biosciences Reports First Quarter 2024 Financial Results
PR NewswireNeurocrine Biosciences Announces U.S. FDA Approval of INGREZZA® SPRINKLE (valbenazine) Capsules
PR NewswireNeurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community
PR NewswireNeurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
PR NewswireNeurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results
PR NewswireNeurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder
PR NewswireNeurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
PR NewswireNeurocrine Biosciences to Participate at Virtual Investor Conferences in March
PR NewswireNeurocrine Biosciences to Participate at Investor Conferences in March
PR NewswireNeurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024
PR NewswireNeurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2023 Financial Results
PR NewswireNeurocrine Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
PR NewswireNeurocrine Biosciences Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Crinecerfont in Congenital Adrenal Hyperplasia
PR NewswireNeurocrine Biosciences to Host Analyst Day on December 5, 2023
PR NewswireNeurocrine Biosciences Announces Settlement of INGREZZA Abbreviated New Drug Application (ANDA) Litigation
PR NewswireNeurocrine Biosciences Provides Development Pipeline Update
PR NewswireNeurocrine Biosciences Launches Interactive Digital Tool for use by Healthcare Providers to Help Expand Education on Identifying and Diagnosing Tardive Dyskinesia
PR NewswireNeurocrine Biosciences to Present at the Jefferies London Healthcare Conference
PR NewswireNeurocrine Biosciences® Presents INGREZZA® (valbenazine) Capsules Interim Data Demonstrating Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 50 at Huntington Stu...
PR NewswireNeurocrine Biosciences Reports Third Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance
PR NewswireNeurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2023 Financial Results
PR NewswireNeurocrine Biosciences Announces Phase 3 Pediatric Study Results of Crinecerfont in Children and Adolescents for the Treatment of Congenital Adrenal Hyperplasia Met Primary and Key Secondary Endpoints
PR NewswireNeurocrine Biosciences Announces U.S. FDA Accepts New Drug Application for INGREZZA® (valbenazine) Oral Granules Sprinkle Formulation
PR NewswireNeurocrine Biosciences Announces Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia (CAH)
PR NewswireNeurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
PR NewswireNeurocrine Biosciences to Present at Upcoming Investor Conferences in September
PR NewswireNeurocrine Biosciences Presents Data at MDS International Congress of Parkinson's Disease and Movement Disorders® Demonstrating Comparable Improvement Over Time in Tardive Dyskinesia Severity and ...

Neurocrine Biosciences News

Neurocrine Biosciences News: auf dieser Seite finden Sie alle Neurocrine Biosciences News und Nachrichten zur Neurocrine Biosciences Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Neurocrine Biosciences News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Neurocrine Biosciences News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.